Skip to the story
All stories

Trump administration strikes drug pricing deals with nine companies

New agreements aim to lower prescription drug costs for state Medicaid programs.

AI-assisted coverage comparison, editor-supervised · How this was made

Published
Trump administration strikes drug pricing deals with nine companies

What this story says

  • Nine pharmaceutical companies have agreed to sell medications at lower prices to state Medicaid programs.
  • These deals are part of the administration's push to make healthcare more affordable.
  • The companies also committed to invest at least $19.6 billion in U.S. manufacturing.
  • Four of the companies will donate active pharmaceutical ingredients to the federal reserve.

Who covered it

Left 9%(6)Centre 45%(29)Right 46%(30)

Percentages are shares of the 65 outlets carrying a published leaning rating. 26 of the 91 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .

Trust

78/100

Craft

68/100

Hype

25/100

91 sources · methodology

Thin on the left so far

Only 6 of the 65 outlets with a published leaning rating that ran this story are rated left.

This story is still being watched, so it is a count and not yet a finding. Coverage keeps arriving for hours after an event, and a side that has published nothing this morning may publish by tonight. If it is still true when we stop checking, we will say so plainly.

The Trump administration has reached new drug pricing agreements with nine pharmaceutical companies. These companies have voluntarily agreed to sell their medications at lower prices to state Medicaid programs. The deals aim to align U.S. prices with those paid in other developed countries, a policy the administration refers to as 'most favored nation' pricing.

In addition to price reductions, the companies committed to invest at least $19.6 billion collectively in U.S. manufacturing. Four of the participating companies, Astellas, Sun Pharma, Teva, and UCB, also agreed to donate active pharmaceutical ingredients to the federal government's strategic reserve. This initiative is intended to reduce reliance on foreign supply chains and prepare for emergencies.

Disagreement on coverage percentage

CNBC reports the administration has now reached drug pricing deals with 26 pharmaceutical companies, representing 90% of the domestic pharmaceutical market. The Daily Bo Snerdley digest states the agreements cover 89% of a market segment, while Moncloa and Spectrum News 13 digests report 89% of the US branded market is covered. USA Today reports the new deals cover 89% of brand name drugs.

What the coverage left out

None of the left-rated digests mention the specific commitment by Astellas, Sun Pharma, Teva, and UCB to donate active pharmaceutical ingredients to the federal reserve. Similarly, none of the centre-rated digests mention this specific commitment. The right-rated digests also do not mention the donation of active pharmaceutical ingredients.

Still developing. We have re-checked which outlets are covering this 1 time, most recently on 1 Sept 2026, 12:30, and will add the sides that appear.

How each side covered it

Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.

Left

6 rated outlets

  • Left-rated reports highlighted President Trump's announcement of new drug pricing deals with nine pharmaceutical companies. Several reports noted the administration's claim that these agreements would lower prices for state Medicaid programs. Common Dreams published a headline calling the deals a "farce" and indicated plans for a Freedom of Information request to obtain the texts of the agreements. NBC News provided live coverage of Trump's announcement on healthcare affordability.

Centre

29 rated outlets

  • Centre-rated reports focused on the Trump administration's announcement of new drug pricing agreements with nine pharmaceutical companies, including CSL, Astellas, and Sun Pharma. These reports mentioned the deals are part of a push to make healthcare more affordable for Americans. Several digests noted that companies agreeing to lower drug prices also announced U.S. research and development investments.

Right

30 rated outlets

  • Right-rated reports highlighted President Trump's announcement of new drug pricing deals with nine pharmaceutical companies, with The Daily Bo Snerdley projecting $600 billion in drug savings. American Greatness also reported on deals projected to save Americans $600 billion. India Today's digest noted Sun Pharma's agreement to offer MFN pricing in exchange for a delay in tariffs, framing it as a shift in strategy for Indian drugmakers. RedState reported that Trump's drug pricing push now covers 89 percent of the branded drug market.

Questions about this coverage

How did the left and right cover Trump administration strikes drug pricing deals with nine companies?
Of the 65 outlets on this story carrying a published leaning rating, 9% are rated left, 45% are rated centre, 46% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 91. The sections above set out what each side emphasised, in its own terms.
Is Trump administration strikes drug pricing deals with nine companies left or right?
Neither side dominates it. Of the 65 rated outlets on this story, 9% are rated left, 45% are rated centre, 46% are rated right, and no side holds the 70% this site would want before calling a field one-sided. A story is not left or right in any case; the outlets that carried it are what carry ratings.
Is the coverage of Trump administration strikes drug pricing deals with nine companies biased?
Trump administration strikes drug pricing deals with nine companies is one event reported by 91 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
Which side is not reporting Trump administration strikes drug pricing deals with nine companies?
When we first saw this story, outlets rated left had barely covered it. Coverage accretes for hours after an event, so that is where to look rather than a verdict — the split above is the current count, and it is the one to read.
Which outlets covered Trump administration strikes drug pricing deals with nine companies?
91 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
How many drugmakers agreed to lower prices?
Nine pharmaceutical companies have agreed to voluntarily sell their medications at lower prices to state Medicaid programs. This brings the total number of companies participating in the administration's drug pricing agreements to 26.
What is the 'most favored nation' policy?
The 'most favored nation' policy, as described by the administration, aims to link U.S. drug prices to the lowest prices paid in other developed countries. The goal is to make healthcare more affordable for Americans.
What investments are companies making?
The nine companies that agreed to lower prices have also committed to investing at least $19.6 billion collectively in U.S. manufacturing. Four of these companies will also donate active pharmaceutical ingredients to the federal reserve.

Read it at the source

98 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.

Left

6

Centre

33
Show 25 more

Right

32
Show 24 more

Not rated

27
Show 19 more

How did this read?

About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.

Trump administration strikes drug pricing deals with nine companies | MediaBias News